Unstable angina/ NSTEMI resident survival guide: Difference between revisions
(→Do´s) |
(→Do´s) |
||
Line 109: | Line 109: | ||
* Beta-bloquers should be administer to all patients with hypertension, tachycardia or ongoing chest pain. <ref name="pmid17502569">{{cite journal| author=Rosendorff C, Black HR, Cannon CP, Gersh BJ, Gore J, Izzo JL et al.| title=Treatment of hypertension in the prevention and management of ischemic heart disease: a scientific statement from the American Heart Association Council for High Blood Pressure Research and the Councils on Clinical Cardiology and Epidemiology and Prevention. | journal=Circulation | year= 2007 | volume= 115 | issue= 21 | pages= 2761-88 | pmid=17502569 | doi=10.1161/CIRCULATIONAHA.107.183885 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=17502569 }} </ref> <ref name="pmid15288162">{{cite journal| author=López-Sendón J, Swedberg K, McMurray J, Tamargo J, Maggioni AP, Dargie H et al.| title=Expert consensus document on beta-adrenergic receptor blockers. | journal=Eur Heart J | year= 2004 | volume= 25 | issue= 15 | pages= 1341-62 | pmid=15288162 | doi=10.1016/j.ehj.2004.06.002 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=15288162 }} </ref> | * Beta-bloquers should be administer to all patients with hypertension, tachycardia or ongoing chest pain. <ref name="pmid17502569">{{cite journal| author=Rosendorff C, Black HR, Cannon CP, Gersh BJ, Gore J, Izzo JL et al.| title=Treatment of hypertension in the prevention and management of ischemic heart disease: a scientific statement from the American Heart Association Council for High Blood Pressure Research and the Councils on Clinical Cardiology and Epidemiology and Prevention. | journal=Circulation | year= 2007 | volume= 115 | issue= 21 | pages= 2761-88 | pmid=17502569 | doi=10.1161/CIRCULATIONAHA.107.183885 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=17502569 }} </ref> <ref name="pmid15288162">{{cite journal| author=López-Sendón J, Swedberg K, McMurray J, Tamargo J, Maggioni AP, Dargie H et al.| title=Expert consensus document on beta-adrenergic receptor blockers. | journal=Eur Heart J | year= 2004 | volume= 25 | issue= 15 | pages= 1341-62 | pmid=15288162 | doi=10.1016/j.ehj.2004.06.002 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=15288162 }} </ref> | ||
* Statins should be administer to all patients with unstable angina. The recommendation is atorvastatin 80mg/day <ref name="pmid15007110">{{cite journal| author=Cannon CP, Braunwald E, McCabe CH, Rader DJ, Rouleau JL, Belder R et al.| title=Intensive versus moderate lipid lowering with statins after acute coronary syndromes. | journal=N Engl J Med | year= 2004 | volume= 350 | issue= 15 | pages= 1495-504 | pmid=15007110 | doi=10.1056/NEJMoa040583 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=15007110 }} [http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=15341453 Review in: ACP J Club. 2004 Sep-Oct;141(2):33] </ref> <ref name="pmid11277825">{{cite journal| author=Schwartz GG, Olsson AG, Ezekowitz MD, Ganz P, Oliver MF, Waters D et al.| title=Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. | journal=JAMA | year= 2001 | volume= 285 | issue= 13 | pages= 1711-8 | pmid=11277825 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=11277825 }} </ref> | * Statins should be administer to all patients with unstable angina. The recommendation is atorvastatin 80mg/day <ref name="pmid15007110">{{cite journal| author=Cannon CP, Braunwald E, McCabe CH, Rader DJ, Rouleau JL, Belder R et al.| title=Intensive versus moderate lipid lowering with statins after acute coronary syndromes. | journal=N Engl J Med | year= 2004 | volume= 350 | issue= 15 | pages= 1495-504 | pmid=15007110 | doi=10.1056/NEJMoa040583 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=15007110 }} [http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=15341453 Review in: ACP J Club. 2004 Sep-Oct;141(2):33] </ref> <ref name="pmid11277825">{{cite journal| author=Schwartz GG, Olsson AG, Ezekowitz MD, Ganz P, Oliver MF, Waters D et al.| title=Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. | journal=JAMA | year= 2001 | volume= 285 | issue= 13 | pages= 1711-8 | pmid=11277825 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=11277825 }} </ref> | ||
*Non-steroidal anti-inflamatory drugs should be discontinued immediately. <ref name="pmid21224324">{{cite journal| author=Trelle S, Reichenbach S, Wandel S, Hildebrand P, Tschannen B, Villiger PM et al.| title=Cardiovascular safety of non-steroidal anti-inflammatory drugs: network meta-analysis. | journal=BMJ | year= 2011 | volume= 342 | issue= | pages= c7086 | pmid=21224324 | doi=10.1136/bmj.c7086 | pmc=PMC3019238 | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=21224324 }} [http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=21460398 Review in: Evid Based Med. 2011 Oct;16(5):142-3] </ref> | *Non-steroidal anti-inflamatory drugs should be discontinued immediately. <ref name="pmid21224324">{{cite journal| author=Trelle S, Reichenbach S, Wandel S, Hildebrand P, Tschannen B, Villiger PM et al.| title=Cardiovascular safety of non-steroidal anti-inflammatory drugs: network meta-analysis. | journal=BMJ | year= 2011 | volume= 342 | issue= | pages= c7086 | pmid=21224324 | doi=10.1136/bmj.c7086 | pmc=PMC3019238 | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=21224324 }} [http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=21460398 Review in: Evid Based Med. 2011 Oct;16(5):142-3] </ref> <ref name="pmid23726390">{{cite journal| author=Coxib and traditional NSAID Trialists' (CNT) Collaboration. Bhala N, Emberson J, Merhi A, Abramson S, Arber N et al.| title=Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials. | journal=Lancet | year= 2013 | volume= 382 | issue= 9894 | pages= 769-79 | pmid=23726390 | doi=10.1016/S0140-6736(13)60900-9 | pmc=PMC3778977 | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=23726390 }} [http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=24126661 Review in: Ann Intern Med. 2013 Oct 15;159(8):JC12] </ref> | ||
* P2Y12 platelet inhibitor therapy should be continued for 12 months with a maintenance dose of either | * P2Y12 platelet inhibitor therapy should be continued for 12 months with a maintenance dose of either <ref name="pmid18574276">{{cite journal| author=Harrington RA, Becker RC, Cannon CP, Gutterman D, Lincoff AM, Popma JJ et al.| title=Antithrombotic therapy for non-ST-segment elevation acute coronary syndromes: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). | journal=Chest | year= 2008 | volume= 133 | issue= 6 Suppl | pages= 670S-707S | pmid=18574276 | doi=10.1378/chest.08-0691 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=18574276 }} </ref> | ||
** Clopidogrel - 75mg per day | ** Clopidogrel - 75mg per day | ||
**Prasogrel - 10mg per day | ** Prasogrel - 10mg per day | ||
**Ticagrelor - 90mg twice a day | ** Ticagrelor - 90mg twice a day | ||
==Don´ts== | ==Don´ts== |
Revision as of 20:05, 27 January 2014
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Definition
Unstable angina is an unexpected chest pain while resting or sleeping,that could get worse with time lasting at least 20 minutes up to 30 minutes. It is caused by a temporary reduced blood flow, resulting in a decreased oxygen supply to the myocardial tissue.
Causes
Life Threatening Causes
- Reduced myocardial perfussion
- Mycordial infarction
- Cocaine-associated mycoardial infarction
Common Causes
- Atherosclerosis
- Non-occlusive thrombus
Management
Diagnosis
CHARACTERIZE THE SYMPTOMS ❑ Chest pain or discomfort while resting ❑ The pain is longer than 20 minutes | |||||||
PERSONAL HISTORY ❑ Age | |||||||
PHYSICAL EXAMINATION ❑ Measure blood pressure | |||||||
LABS & TESTS ❑ EKG | |||||||
Treatment
❑ Administer 300mg Aspirin immediately after hospital admission ❑ Administer oxygen in patients with saturation <90% | |||||||||||||||||||||||||||||||||||||||||
Determine Risk of adverse coronary event (TIMI) | |||||||||||||||||||||||||||||||||||||||||
LOW RISK Initial conservative strategy | HIGH RISK Initial invasive strategy | ||||||||||||||||||||||||||||||||||||||||
❑ Administer 300mg of copidogrel ❑ Administer fondoparinaux or UFH in case of renal failure | ❑ Administer IV GP IIb/IIIa inhibitors (eptifibatide or tirofiban) OR ❑ Administer Bivalirudin | ||||||||||||||||||||||||||||||||||||||||
Perform a Stress test | Angiography | ||||||||||||||||||||||||||||||||||||||||
LOW RISK | HIGH RISK | NEGATIVE | POSITIVE | ||||||||||||||||||||||||||||||||||||||
Recurrent symptoms? | ❑ Continue Aspirin ❑ Continue with clopidrogel or ticagelor for 12 months ❑ Discontinue with GP inhibitors ❑ UFH (for 48hrs) or Enoxiparin (for 8 dyas) | ||||||||||||||||||||||||||||||||||||||||
NO | ❑ heart faillure ❑ serious arrhythmias ❑ subsequent isquemia | ||||||||||||||||||||||||||||||||||||||||
Continue Aspirin ❑ Continue with clopidrogel or ticagelor for 12 months ❑ Discontinue with GP inhibitors ❑ UFH (for 48hrs) or Enoxiparin (for 8 dyas | PCI ❑ Administer clopidogrel 24 hrs before | CABG ❑ Continue aspirin + UFH | |||||||||||||||||||||||||||||||||||||||
INTENSIVE STRATEGY - ANGIOGRAPHY | |||||||||||||||||||||||||||||||||||||||||
NEGATIVE | POSITIVE | ||||||||||||||||||||||||||||||||||||||||
❑ Continue Aspirin ❑ Continue with clopidrogel or ticagelor for 12 months ❑ Discontinue with GP inhibitors ❑ UFH (for 48hrs) or Enoxiparin (for 8 dyas) | PCI ❑ Administer clopidogrel 24 hrs before | CABG ❑ Continue aspirin + UFH | |||||||||||||||||||||||||||||||||||||||
Do´s
- Administer 300 mg of clopidogrel as initial treatment instead of aspirin in case of gastrointestinal intolerance of hypersensitivity reaction.
- Oxygen must be administered in patients with arteria saturation less than 90% or in respiratory distress [1]
- Administer sublingual nitroglycerin in patients with ischemic chest pain. IV should be administer in patients with persistent chest pain after three sublingual nitroglycerins. [2]
- Nitroglycerin should be administer to all patients with hypertension or heart failure.
- Beta-bloquers should be administer to all patients with hypertension, tachycardia or ongoing chest pain. [3] [4]
- Statins should be administer to all patients with unstable angina. The recommendation is atorvastatin 80mg/day [5] [6]
- Non-steroidal anti-inflamatory drugs should be discontinued immediately. [7] [8]
- P2Y12 platelet inhibitor therapy should be continued for 12 months with a maintenance dose of either [9]
- Clopidogrel - 75mg per day
- Prasogrel - 10mg per day
- Ticagrelor - 90mg twice a day
Don´ts
References
- ↑ name="pmid23554440">{{cite journal| author=Shuvy M, Atar D, Gabriel Steg P, Halvorsen S, Jolly S, Yusuf S et al.| title=Oxygen therapy in acute coronary syndrome: are the benefits worth the risk? | journal=Eur Heart J | year= 2013 | volume= 34 | issue= 22 | pages= 1630-5 | pmid=23554440 | doi=10.1093/eurheartj/eht110 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?
- ↑ Kaplan K, Davison R, Parker M, Przybylek J, Teagarden JR, Lesch M (1983). "Intravenous nitroglycerin for the treatment of angina at rest unresponsive to standard nitrate therapy". Am J Cardiol. 51 (5): 694–8. PMID 6402912.
- ↑ Rosendorff C, Black HR, Cannon CP, Gersh BJ, Gore J, Izzo JL; et al. (2007). "Treatment of hypertension in the prevention and management of ischemic heart disease: a scientific statement from the American Heart Association Council for High Blood Pressure Research and the Councils on Clinical Cardiology and Epidemiology and Prevention". Circulation. 115 (21): 2761–88. doi:10.1161/CIRCULATIONAHA.107.183885. PMID 17502569.
- ↑ López-Sendón J, Swedberg K, McMurray J, Tamargo J, Maggioni AP, Dargie H; et al. (2004). "Expert consensus document on beta-adrenergic receptor blockers". Eur Heart J. 25 (15): 1341–62. doi:10.1016/j.ehj.2004.06.002. PMID 15288162.
- ↑ Cannon CP, Braunwald E, McCabe CH, Rader DJ, Rouleau JL, Belder R; et al. (2004). "Intensive versus moderate lipid lowering with statins after acute coronary syndromes". N Engl J Med. 350 (15): 1495–504. doi:10.1056/NEJMoa040583. PMID 15007110. Review in: ACP J Club. 2004 Sep-Oct;141(2):33
- ↑ Schwartz GG, Olsson AG, Ezekowitz MD, Ganz P, Oliver MF, Waters D; et al. (2001). "Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial". JAMA. 285 (13): 1711–8. PMID 11277825.
- ↑ Trelle S, Reichenbach S, Wandel S, Hildebrand P, Tschannen B, Villiger PM; et al. (2011). "Cardiovascular safety of non-steroidal anti-inflammatory drugs: network meta-analysis". BMJ. 342: c7086. doi:10.1136/bmj.c7086. PMC 3019238. PMID 21224324. Review in: Evid Based Med. 2011 Oct;16(5):142-3
- ↑ Coxib and traditional NSAID Trialists' (CNT) Collaboration. Bhala N, Emberson J, Merhi A, Abramson S, Arber N; et al. (2013). "Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials". Lancet. 382 (9894): 769–79. doi:10.1016/S0140-6736(13)60900-9. PMC 3778977. PMID 23726390. Review in: Ann Intern Med. 2013 Oct 15;159(8):JC12
- ↑ Harrington RA, Becker RC, Cannon CP, Gutterman D, Lincoff AM, Popma JJ; et al. (2008). "Antithrombotic therapy for non-ST-segment elevation acute coronary syndromes: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)". Chest. 133 (6 Suppl): 670S–707S. doi:10.1378/chest.08-0691. PMID 18574276.